Nippon Shinyaku Co., Ltd. (TSE: 4516) The Company's principal activity is to specialize in the development, manufacture and sale of ethical drugs, especially for the treatment of contemporary diseases such as cardiovascular, gastrointestinal, urological, inflammatory and allergic diseases. The operations are carried out through two divisions: Pharmaceuticals and Foodstuff. The major products of the Company consist of nervous and respiratory drugs, cardiovascular and metabolic drugs, urological drugs, gastrointestinal drugs, anticancer drugs as well as other drugs. Pharmaceuticals (nervous and respiratory drugs, metabolic drugs) accounted for 83% of fiscal 2002 revenues and Foodstuff, 17%.
日本新药株式会社
TYO:4516 ISIN:JP3717600005
新闻
李氏大药厂控股有限公司(「李氏大药厂」或「集团」;HKG:8221)今天宣布截至2009年3月31日止三个月未经审核的第一季度业绩(「回顾期内」)。
###
16,032 公司背景浏览
- 本页浏览人次: (过去7日: 19) (过去30日: 105) (自发布以来: 6672)